United Kingdom · Motion · Early Day Motion
EDM 957
COST-EFFECTIVENESS OF BETA INTERFERON
Introduced
11 July 2000
Last action
11 July 2000 · Early Day Motion
Status
0
Sponsors
Paul Burstow
Subjects
Discovery layer
Source updated
11 July 2000
Summary
That this House notes that new research has demonstrated that the cost of beta interferon should be calculated on the assumption that its benefits can be long-term and that the cost of the drug is outweighted by the cost to society of caring for a patient disabled by MS; and calls on the National Institute for Clinical Excellence to examine the findings reported in the journal Pharmaco Economics and to take evidence from people with MS.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
11 July 2000
Early Day Motion
That this House notes that new research has demonstrated that the cost of beta interferon should be calculated on the assumption that its benefits can be long-term and that the cost of the drug is outweighted by the cost to society of caring for a patient disabled by MS; and calls on the National Institute for Clinical Excellence to examine the findings reported in the journal Pharmaco Economics and to take evidence from people with MS.
Source: Early Day Motion
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- Paul Burstow · Liberal Democrat · Primary sponsor
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://edm.parliament.uk/early-day-motions/17779
- Open data entity: https://oralquestionsandmotions-api.parliament.uk/EarlyDayMotions/list
- uk · edm-17779 · source updated 11 July 2000